The University makes its innovative know-how, as well as the experience and expertise of its professors and researchers, available to companies and public entities (https://www.uniroma1.it/it/pagina/contratti-conto-terzi).
Third-party activities (attività conto terzi), provided for by Art. 66 of Presidential Decree 11.7.1980, n. 382, pursue the University's objective of strengthening its ties with the local area by offering quality services that enhance academic expertise, compatible with its scientific and educational functions and within the scope of its institutional and statutory purposes. An increasing number of public and private entities turn to the University to commission projects, research, and consultancy services across the manifold areas of expertise available within the institution.
The Department of Experimental Medicine has signed agreements for third-party activities with various economic stakeholders for specialised research activities.
The agreements active as of December 31, 2022 are:
| N. protocollo | STUDY | PERSON IN CHARGE |
|---|---|---|
| Prot. 237/2020 | Novo Nordisk Studio NN9535-4321 | Prof. CAVALLO |
| Prot. 300/2020 | Opis Srl Studio GLARGR09384- RESTORE-2 | Prof. BUZZETTI |
| Prot. 1163/2020 | Parexel International Studio NN9535-4549 – SURE | Prof. BUZZETTI |
| Prot. 1639/2020 | Icon Public Limited C. Studio CORT125134-452 | Prof. ISIDORI |
| Prot. 2320/2020 | Coresearch Srl Studio Annali AMD | Prof. BUZZETTI |
| Prot. 2367/2020 | Dompé Farmaceutici SpA Studio LDX0419 | Prof. BUZZETTI |
| Prot. 483/2021 | Medineos SURL Studio 6153 REX – NN9068-4740 | Prof. BUZZETTI |
| Prot. 620/2021 | Icon Clinical Research L. Studio CORT125134-456 | Prof. ISIDORI |
| Prot. 682/2021 | Dompé Farmaceutici spa Studio LDX0319 | Prof. BUZZETTI |
| Prot. 1329/2021 | Neurocrine Biosciences Studio NBI-74788-CAH3003 | Prof. ISIDORI |
| Prot. 1438/2021 | Scope International AG Studio HDR-0320-DR | Prof. MORANO |
| Prot. 1457/2021 | Novo Nordisk SpA Studio NN1436-4480 | Prof. BUZZETTI |
| Prot. 1677/2021 | Novo Nordisk SpA Studio NN1436-4625 | Prof. BUZZETTI |
| Prot. 1786/2021 | Azienda Ospedalieri Ospedali Riuniti Marche Nord | Prof. ANGELONI |
| Prot. 2615/2022 | Ascendis Pharma Studio TCH-306 | Prof. ISIDORI |
| Prot. 4300/2022 | Novo Nordisk Spa Studio REDEFINE-1 | Prof. GNESSI |
| Prot. 4303/ 202 | 2 Astrazeneca SpA Studio D5671C00006 | Prof. CAVALLO |
